Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Hengrui discovers, makes, and sells medicines, mainly cancer drugs, in China and around the world.
Hengrui Pharma is one of China's biggest makers of prescription medicines, and its specialty is cancer treatment. Hospitals and doctors prescribe its drugs to patients, and the company also sells medicines for other conditions like pain, infections, and metabolic disease. It does the whole job itself: research labs dream up new molecules, its factories turn them into pills and injectables, and its sales force gets them into hospitals across China.
For most of its history, the business ran on copycat drugs — generic versions of medicines that were already off patent, plus slightly improved versions of existing drugs. That was a steady, reliable business in a country where hospitals needed lots of affordable medicine. The catch is that generic drugs are a commodity: when many companies make the same pill, the price falls, and China's government has repeatedly forced prices down through bulk purchasing programs. So the real prize became original drugs that Hengrui owns outright. That bet has been paying off. Hengrui has built a deep pipeline of its own cancer medicines, especially a class called PD-1 inhibitors that unleash the body's immune system against tumors. It has also expanded overseas through licensing deals, where big Western drugmakers pay upfront and promise future royalties to sell Hengrui's molecules in their markets. That's a much better business than generics: one successful drug can earn money for years, protected by patents.
The risks are real. Chinese drug prices are under government pressure, competition in hot areas like cancer immunotherapy is fierce, and developing a new drug is a slow, expensive gamble that often fails. But Hengrui spends heavily on research, which is the engine of the whole thing, and its mix is shifting from cheap copies toward original medicines. Investors treat it as one of the closest things China has to a global pharmaceutical innovator.
Saved answer · last researched 12 Nov 2026